Newsroom Archives - Page 13 of 24 - Spectral Medical Inc

Spectral Medical Provides Update on Tigris Clinical Trial and Other Business Developments

50 Patients Randomized to Date out of the 150 Total Target to be Enrolled Reports Significant Uptick in Screening and Enrollment Activities TORONTO, Ontario–January 12, 2023 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic...

Spectral Medical Announces Strategic Joint Venture with Infomed to Accelerate Commercialization of DIMI and SAMI Dialysis Devices.

Spectral to receive a significant equity stake in the joint venture, while eliminating its need to fund future capital requirements for SAMI and DIMI TORONTO, Ontario–December 13, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage...

Spectral Medical Inc. Closes $10.8 Million Public Offering and Concurrent Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Ontario– November 2, 2022 – Spectral Medical Inc. (TSX: EDT) (“Spectral” or the “Company”) is pleased to announce that it has closed its previously announced...

Spectral Medical Inc. Announces Pricing of Previously Announced Offering

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Ontario– October 6, 2022 – Spectral Medical Inc. (TSX: EDT) (“Spectral” or the “Company”) is pleased to announce that further to its previously proposed...

Spectral Medical Inc. Announces Proposed Public Offering of Units and Private Placement of Notes

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Ontario– October 5, 2022 – Spectral Medical Inc. (TSX: EDT) (“Spectral” or the “Company”) is pleased to announce the launch of a proposed prospectus offering of...

Spectral Medical Provides Update on Tigris Clinical Trial

Robust recruitment activities experienced in closing weeks of September 44 patients now enrolled TORONTO, Canada – October 4, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for...

« Older Entries

Next Entries »

EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.